Suppr超能文献

含有碱性取代基的三环黄嘌呤衍生物:腺苷受体亲和力及与药物相关的性质

Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties.

作者信息

Załuski Michał, Stanuch Katarzyna, Karcz Tadeusz, Hinz Sonja, Latacz Gniewomir, Szymańska Ewa, Schabikowski Jakub, Doroż-Płonka Agata, Handzlik Jadwiga, Drabczyńska Anna, Müller Christa E, Kieć-Kononowicz Katarzyna

机构信息

Department of Technology and Biotechnology of Drugs , Faculty of Pharmacy , Jagiellonian University Medical College , Kraków , Poland . Email:

PharmaCenter Bonn , Pharmaceutical Institute , Pharmaceutical Chemistry I , University of Bonn , An der Immenburg 4 , 53121 Bonn , Germany.

出版信息

Medchemcomm. 2018 May 14;9(6):951-962. doi: 10.1039/c8md00070k. eCollection 2018 Jun 1.

Abstract

A library of 27 novel amide derivatives of annelated xanthines was designed and synthesized. The new compounds represent 1,3-dipropyl- and 1,3-dibutyl-pyrimido[2,1-]purinedione-9-ethylphenoxy derivatives including a CHCONH linker between the (CH)-amino group and the phenoxy moiety. A synthetic strategy to obtain the final products was developed involving solvent-free microwave irradiation. The new compounds were evaluated for their adenosine receptor (AR) affinities. The most potent derivatives contained a terminal tertiary amino function. Compounds with nanomolar AR affinities and at the same time high water-solubility were obtained (A ( = 24-605 nM), A ( = 242-1250 nM), A ( = 66-911 nM) and A ( = 155-1000 nM)). 2-(4-(2-(1,3-Dibutyl-2,4-dioxo-1,2,3,4,7,8-hexahydropyrimido[2,1-]purin-9(6)-yl)ethyl)phenoxy)--(3-(diethylamino)propyl)acetamide () and the corresponding -(2-(pyrrolidin-1-yl)ethyl)acetamide () were found to be the most potent antagonists of the present series. While showed CYP inhibition and moderate metabolic stability, was found to possess suitable properties for applications. In an attempt to explain the affinity data for the synthesized compounds, molecular modeling and docking studies were performed using homology models of A and A adenosine receptors. The potent compound was used as an example for discussion of the possible ligand-protein interactions. Moreover, the compounds showed high water-solubility indicating that the approach of introducing a basic side chain was successful for the class of generally poorly soluble AR antagonists.

摘要

设计并合成了一个包含27种新型稠合黄嘌呤酰胺衍生物的文库。新化合物代表1,3 - 二丙基 - 和1,3 - 二丁基 - 嘧啶并[2,1 - ]嘌呤二酮 - 9 - 乙基苯氧基衍生物,在(CH)-氨基和苯氧基部分之间含有一个CHCONH连接基。开发了一种采用无溶剂微波辐射的合成策略来获得最终产物。对新化合物进行了腺苷受体(AR)亲和力评估。最有效的衍生物含有末端叔氨基官能团。获得了具有纳摩尔级AR亲和力且同时具有高水溶性的化合物(A = 24 - 605 nM)、A = 242 - 1250 nM)、A = 66 - 911 nM)和A = 155 - 1000 nM)。发现2-(4-(2-(1,3 - 二丁基 - 2,4 - 二氧代 - 1,2,3,4,7,8 - 六氢嘧啶并[2,1 - ]嘌呤 - 9(6)-基)乙基)苯氧基)--(3-(二乙氨基)丙基)乙酰胺()和相应的-(2-(吡咯烷 - 1 - 基)乙基)乙酰胺()是本系列中最有效的拮抗剂。虽然表现出CYP抑制和中等代谢稳定性,但发现具有适合应用的性质。为了解释合成化合物的亲和力数据,使用A和A腺苷受体的同源模型进行了分子建模和对接研究。以强效化合物为例讨论了可能的配体 - 蛋白质相互作用。此外,这些化合物显示出高水溶性,表明引入碱性侧链的方法对于一般难溶性AR拮抗剂类别是成功的。

相似文献

本文引用的文献

3
Medicinal chemistry of adenosine, P2Y and P2X receptors.腺苷、P2Y 和 P2X 受体的药物化学
Neuropharmacology. 2016 May;104:31-49. doi: 10.1016/j.neuropharm.2015.12.001. Epub 2015 Dec 12.
4
A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy.A2aR拮抗剂:癌症免疫疗法的新一代检查点阻断剂。
Comput Struct Biotechnol J. 2015 Apr 8;13:265-72. doi: 10.1016/j.csbj.2015.03.008. eCollection 2015.
5
The A3 adenosine receptor: history and perspectives.A3 腺苷受体:历史与展望。
Pharmacol Rev. 2015;67(1):74-102. doi: 10.1124/pr.113.008540.
6
Aryl-1,3,5-triazine derivatives as histamine H4 receptor ligands.芳基-1,3,5-三嗪衍生物作为组氨酸 H4 受体配体。
Eur J Med Chem. 2014 Aug 18;83:534-46. doi: 10.1016/j.ejmech.2014.06.032. Epub 2014 Jun 17.
8
Adenosine receptors: expression, function and regulation.腺苷受体:表达、功能与调控
Int J Mol Sci. 2014 Jan 28;15(2):2024-52. doi: 10.3390/ijms15022024.
10
Istradefylline: first global approval.依曲替酯:全球首次获批。
Drugs. 2013 Jun;73(8):875-82. doi: 10.1007/s40265-013-0066-7.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验